73 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2029. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Jun 2029
Next term end
31
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2031 · High confidence
Also notable
Ends Oct 2030 · High confidence
Also notable
Ends Nov 2031 · High confidence
Compositions and Methods Comprising Histidyl-Trna Synthetase Splice Variants Having Non-Canonical Biological Activities
US 8,404,242
The most cited patent in this portfolio, cited by 175 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2031.
Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities
US 8,404,471
Cited by 153 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Innovative Discovery of Therapeutic, Diagnostic, and Antibody Compositions Related to Protein Fragments of Alanyl-Trna Synthetases
US 8,993,723
Cited by 81 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 19, 2026
- 3 fees due Dec 23 to 30, 2026 · next Dec 23
- 1 fee due Mar 26, 2027The maintenance fee for Compositions and Methods for Treating Lung Inflammation (US 11,767,520) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 1 fee due Apr 13, 2027The maintenance fee for Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities (US 9,157,076) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 2 fees due May 7 to 12, 2027 · next May 7
- 2 fees due Aug 18, 2027
- 3 fees due Oct 19 to 26, 2027 · next Oct 19
Recent changes
- 1 term has ended since Aug 17, 2026
What they patent
The 5 largest of its 31 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,747,840 | Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities In force · High confidence | In force | High confidence | |
| US 9,157,076 | Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities In force · High confidence | In force | High confidence | |
| US 9,585,946 | Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities In force · High confidence | In force | High confidence | |
| US 9,896,680 | Compositions and Methods Comprising Aspartyl-Trna Synthetases Having Non-Canonical Biological Activities In force · High confidence | In force | High confidence | |
| US 8,404,471 | Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities In force · High confidence | In force | High confidence | |
| US 8,404,242 | Compositions and Methods Comprising Histidyl-Trna Synthetase Splice Variants Having Non-Canonical Biological Activities In force · High confidence | In force | High confidence | |
| US 9,540,629 | Innovative Discovery of Therapeutic, Diagnostic, and Antibody Compositions Related to Protein Fragments of Cysteinyl-Trna Synthetase In force · High confidence | In force | High confidence | |
| US 10,717,786 | Innovative Discovery of Therapeutic, Diagnostic, and Antibody Compositions Related to Protein Fragments of Cysteinyl-Trna Synthetase In force · Medium confidence | In force | Medium confidence | |
| US 9,528,103 | Innovative Discovery of Therapeutic, Diagnostic, and Antibody Compositions Related to Protein Fragments of Isoleucyl Trna Synthetases In force · High confidence | In force | High confidence | |
| US 9,580,706 | Innovative Discovery of Therapeutic, Diagnostic, and Antibody Compositions Related to Protein Fragments of Threonyl-Trna Synthetases In force · High confidence | In force | High confidence |
Also on record, not counted in the 73: 7 patents in force now held by others · 12 patents ended · 7 applications pending · 30 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.